Triclosan Demonstrates Synergic Effect with Amphotericin B and Fluconazole and Induces Apoptosis-Like Cell Death in Cryptococcus Neoformans

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2016 Apr 6

PMID 27047474

Citations 13

Authors

Elaheh Movahed

Grace Min Yi Tan

Komathy Munusamy

Tee Cian Yeow

Sun Tee Tay

Won Fen Wong

Chung Yeng Looi

Affiliations

Soon will be listed here.

Abstract

Objectives: Cryptococcus neoformans is an opportunistic fungus that causes fatal meningoencephalitis especially in AIDS patients. There is an increasing need for discovery of new anti-cryptococcal drugs due to emergence of resistance cases in recent years. In this study, we aim to elucidate the antifungal effect of triclosan against C. neoformans.

Methods: Minimal inhibitory concentration (MIC) of triclosan in different C. neoformans strains was first examined. The in vitro interactions between triclosan and two standard anti-fungal drugs (amphotericin B and fluconazole) were further evaluated by microdilution checkerboard assay. Mechanism of triclosan fungicidal activity was then investigated by viewing the cell morphology under transmission electron microscope.

Results: We reported that triclosan potently inhibited the growth of C. neoformans. A combination of triclosan with amphotericin B or with fluconazole enhanced their fungicidal effects. Triclosan-treated C. neoformans displayed characteristics such as nuclear chromatin condensation, extensive intracellular vacuolation and mitochondrial swelling, indicating that triclosan triggered apoptosis-like cell death.

Conclusion: In summary, our report suggests triclosan as an independent drug or synergent for C. neoformans treatment.

Citing Articles

Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis.

Alkashef N, Seleem M PLoS One. 2024; 19(8):e0308216.

PMID: 39088434 PMC: 11293717. DOI: 10.1371/journal.pone.0308216.

Searching for new antifungals for the treatment of cryptococcosis.

de Sousa N, de Almeida J, Frickmann H, Lacerda M, de Souza J Rev Soc Bras Med Trop. 2023; 56:e01212023.

PMID: 37493736 PMC: 10367226. DOI: 10.1590/0037-8682-0121-2023.

Antifungal effect of triclosan on Aspergillus fumigatus: quorum quenching role as a single agent and synergy with liposomal amphotericin-B.

Tamimi R, Kyazze G, Keshavarz T World J Microbiol Biotechnol. 2022; 38(8):142.

PMID: 35718814 PMC: 9206924. DOI: 10.1007/s11274-022-03325-1.

Antimicrobial Potential of Naturally Occurring Bioactive Secondary Metabolites.

Allemailem K J Pharm Bioallied Sci. 2021; 13(2):155-162.

PMID: 34349474 PMC: 8291113. DOI: 10.4103/jpbs.JPBS_753_20.

Antifungal activity of boric acid, triclosan and zinc oxide against different clinically relevant Candida species.

Gavilanes-Martinez M, Coral-Garzon A, Caceres D, Garcia A Mycoses. 2021; 64(9):1045-1052.

PMID: 33969547 PMC: 8373697. DOI: 10.1111/myc.13302.

References

Tay S, Lim H, Tajuddin T, Rohani M, Hamimah H, Thong K . Determination of molecular types and genetic heterogeneity of Cryptococcus neoformans and C. gattii in Malaysia. Med Mycol. 2006; 44(7):617-22. DOI: 10.1080/13693780600857330. View

Villena S, Pinheiro R, Pinheiro C, Nunes M, Takiya C, DosReis G . Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell Microbiol. 2008; 10(6):1274-85. DOI: 10.1111/j.1462-5822.2008.01125.x. View

Rozzelle C, Leonardo J, Li V . Antimicrobial suture wound closure for cerebrospinal fluid shunt surgery: a prospective, double-blinded, randomized controlled trial. J Neurosurg Pediatr. 2008; 2(2):111-7. DOI: 10.3171/PED/2008/2/8/111. View

Schweizer H . Triclosan: a widely used biocide and its link to antibiotics. FEMS Microbiol Lett. 2001; 202(1):1-7. DOI: 10.1111/j.1574-6968.2001.tb10772.x. View

Higgins J, Pinjon E, Oltean H, White T, Kelly S, Martel C . Triclosan antagonizes fluconazole activity against Candida albicans. J Dent Res. 2011; 91(1):65-70. PMC: 3232117. DOI: 10.1177/0022034511425046. View

Hacker G . The morphology of apoptosis. Cell Tissue Res. 2000; 301(1):5-17. DOI: 10.1007/s004410000193. View

Fang J, Stingley R, Beland F, Harrouk W, Lumpkins D, Howard P . Occurrence, efficacy, metabolism, and toxicity of triclosan. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010; 28(3):147-71. DOI: 10.1080/10590501.2010.504978. View

Sanglard D, Ischer F, Monod M, Bille J . Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (Reading). 1997; 143 ( Pt 2):405-416. DOI: 10.1099/00221287-143-2-405. View

Ahn K, Zhao B, Chen J, Cherednichenko G, Sanmarti E, Denison M . In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ Health Perspect. 2008; 116(9):1203-10. PMC: 2535623. DOI: 10.1289/ehp.11200. View

10.

Pancer B, Kott D, Sugai J, Panagakos F, Braun T, Teles R . Effects of triclosan on host response and microbial biomarkers during experimental gingivitis. J Clin Periodontol. 2016; 43(5):435-44. DOI: 10.1111/jcpe.12519. View

11.

Bhargava H, Leonard P . Triclosan: applications and safety. Am J Infect Control. 1996; 24(3):209-18. DOI: 10.1016/s0196-6553(96)90017-6. View

12.

Moss T, Howes D, Williams F . Percutaneous penetration and dermal metabolism of triclosan (2,4, 4'-trichloro-2'-hydroxydiphenyl ether). Food Chem Toxicol. 2000; 38(4):361-70. DOI: 10.1016/s0278-6915(99)00164-7. View

13.

Madeo F, Frohlich E, Frohlich K . A yeast mutant showing diagnostic markers of early and late apoptosis. J Cell Biol. 1997; 139(3):729-34. PMC: 2141703. DOI: 10.1083/jcb.139.3.729. View

14.

Ramsdale M . Programmed cell death in pathogenic fungi. Biochim Biophys Acta. 2008; 1783(7):1369-80. DOI: 10.1016/j.bbamcr.2008.01.021. View

15.

Saag M, Powderly W, Cloud G, Robinson P, GRIECO M, Sharkey P . Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992; 326(2):83-9. DOI: 10.1056/NEJM199201093260202. View

16.

Prasad R, de Wergifosse P, Goffeau A, Balzi E . Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet. 1995; 27(4):320-9. DOI: 10.1007/BF00352101. View

17.

Perfect J, Dismukes W, Dromer F, Goldman D, Graybill J, Hamill R . Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50(3):291-322. PMC: 5826644. DOI: 10.1086/649858. View

18.

Mukherjee P, Sheehan D, Hitchcock C, Ghannoum M . Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005; 18(1):163-94. PMC: 544182. DOI: 10.1128/CMR.18.1.163-194.2005. View

19.

Coleman M, Sahai E, Yeo M, Bosch M, Dewar A, Olson M . Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001; 3(4):339-45. DOI: 10.1038/35070009. View

20.

Manon S, Chaudhuri B, Guerin M . Release of cytochrome c and decrease of cytochrome c oxidase in Bax-expressing yeast cells, and prevention of these effects by coexpression of Bcl-xL. FEBS Lett. 1997; 415(1):29-32. DOI: 10.1016/s0014-5793(97)01087-9. View